CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Clinical trials are an important option to consider for anyone being treated for cancer. Here is a listing of recent CCTG trials that are open to patient enrollment.
For trials by disease location:
This trial is being done to answer the following question: Can survival be improved in your type of brain cancer by using personalized therapy based on changes in the DNA of your tumour? A pre-study screening will test a sample of your tumour tissue for biomarkers to see if you can participate in the study.
The purpose of this study is to find out if the combination of a new drug and a commonly used drug is better than the commonly used drug alone at preventing this type of breast cancer from returning.
The purpose of this study is to determine if observation after surgery is as effective as completing 6 more months of immunotherapy in patients with early-stage triple-negative breast cancer (TNBC) who have completed standard treatment before surgery and who have had a good response.
The purpose of this study is to compare the usual treatment of breast radiation and hormonal drugs after lumpectomy to using hormonal drugs alone for 50 to 70 year old people with low risk breast cancer. The removal of breast radiation from the usual treatment may have no effect on whether your cancer returns, and it could also reduce side effects.
The purpose of this study is to find out if a new drug helps prevent your inflammatory breast cancer from returning when given with radiotherapy.
The purpose of this study is to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women. Testing the addition of chemotherapy to the usual treatment of ovarian function suppression plus hormonal therapy in premenopausal ER-positive/HER2-negative breast cancer patients who are at high risk of cancer returning.
The purpose of this study is to determine which approach, less frequent or more frequent monitoring, will lead to better outcomes for patients with pancreatic cysts.
Currently, the effectiveness of any pancreatic cyst monitoring strategy is unknown. Patients and physicians are eager to learn which strategy is better for this very common condition.
The purpose of this study is to compare the effects on you and your liver cancer of adding a drug that is used on its own to treat this disease to a two-drug combination also used to treat liver cancer, compared to the two-drug combination alone.
The purpose of this study is to find out what effects adding a new drug to the standard treatment has on you and your gastroesophageal cancer compared to the standard treatment given alone.
The purpose of this study is to find out if the approach of avoiding or delaying surgery in patients who have a good response to treatment with chemotherapy and radiation is as good as the usual approach for your esophageal cancer and provides better quality of life.
The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.
Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.
The purpose of this study is to compare the usual approach of chemotherapy plus radiation therapy followed by limited surgery, to using a more intense combination chemotherapy treatment followed by limited surgery.
The study approach without radiation may improve your quality of life and be equally effective at shrinking or stabilizing your cancer.
The purpose of this study is to compare the usual approach of continuing Somatostatin Analogues (SSA) injections during and after Peptide Receptor Radionuclide Therapy (PRRT) to stopping SSA injections when PRRT begins in patients with neuroendocrine tumours (NET).
The purpose of this study is to compare a retreatment with Peptide Receptor Radionuclide Therapy (PRRT) to the standard treatment for your neuroendocrine cancer.
The drug being studied is a new type of drug approved for the treatment of neuroendocrine tumours (NETs). The new drug has been shown to shrink tumours in many people and seems promising, but it is not clear if receiving this drug again can offer better results than standard treatment.
The purpose of this study is to compare the effects on you and your prostate cancer of a new drug compared to other drugs which are the current standard treatment to treat this disease.
The purpose of this study is to compare the effects on you and your prostate cancer of a new drug compared to other drugs which are the current standard treatment for this disease. The addition of the new drug to standard treatment could prevent your prostate cancer from progressing, but this cannot be known for sure. This study will help doctors find out if this different approach is better than the usual one.
The purpose of this study is to compare the effects on you and your prostate cancer of getting a higher dose of radiation therapy given over a shorter period of time compared to the current way radiation therapy is used to treat prostate cancer.
The purpose of this study is to see if adding a new drug to other drugs which are commonly used to treat metastatic urothelial cancer is better than the commonly used drugs alone.
The purpose of this study is to determine whether a blood test can help us make better decisions about who should get immunotherapy after surgery for bladder cancer and which immunotherapy treatment is best.
The study will investigate a new test which can detect bladder cancer DNA in the blood. This is important because this test might indicate the presence of bladder cancer cells somewhere in the body, even if cancer can’t be seen on a scan of the body.
The purpose of this study is to evaluate if specific testing of vulva cancer tissue that is removed by surgery provides useful information to help decide if additional surgery is required or not.
The usual approach to treating early-stage vulvar cancer consists of a single surgery to remove the cancer.
The purpose of this study is to identify people who may not require treatment after surgery or may require less treatment after surgery because their cancer is at such a low risk of coming back based on the specific tumour features found by the laboratory testing and the extent of tumour spread. Receiving no treatment or less treatment can result in no or fewer side effects (fatigue, hair loss, bowel and bladder irritation).
The purpose of this study is to compare the effects on you and your endometrial cancer of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone.
The purpose of this study is to compare the effects on you and your oropharyngeal cancer of radiotherapy to your neck guided by lymph node mapping (lymphatic mapping) using a special X-ray called Single Photon Emission Computed Tomography (SPECT-CT) compared to the current standard treatment where radiotherapy is given to both sides of the neck.
The purpose of this study is to compare the effects on you and your head and neck cancer of a new type of radiation treatment compared with standard radiation therapy.
One of the treatments for multiple myeloma is with three medicines, all continued indefinitely until they stop working, or side effects happen. Two are tablets, and the third is an injection. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.
The purpose of this study is to find out if the addition of a new oral drug to the usual treatment will lower the chance of your primary central nervous system lymphoma (PCNSL) growing or spreading.
The purpose of this study is to compare the usual treatment for your Hodgkin lymphoma, which is a standard combination of four drugs, versus the standard combination with one drug of the combination replaced with a new drug that we hope will be more effective and cause you fewer side effects.
The purpose of this study is to see the effects on you and your lymphoma of a new drug combination compared to other drugs that are currently used in standard treatment.
The purpose of this trial is to find out if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will live longer and have a better quality of life if they start treatment earlier. Some people do not have major symptoms when they are diagnosed with CLL or SLL. Treatment is often started when they show symptoms such as fever, anemia, or night sweats. Studies have shown that early treatment using older chemotherapy drugs doesn’t improve outcomes compared to later treatment.
The purpose of this study is to compare the usual treatment for high-risk acute myeloid leukemia (AML) with four different combinations of treatment.
This trial is part of a larger research study called myeloMATCH which uses biomarker testing to match people to a clinical trial for AML treatment. Find out more >
This trial is the first step in joining a large research study called myeloMATCH.
The purpose of this study is to compare the usual treatment for acute myeloid leukemia (AML) with two different combinations of treatment.
This trial is part of a larger platform study called myeloMATCH > Find out more.
The purpose of this study is to follow (monitor) your disease, by testing tumour tissue and blood samples to learn more about your cancer and how it responds while you are receiving standard of care treatment with a CDK inhibitor with endocrine therapy.
This trial/study consists of a number of independent studies or “substudies”, each of which is testing a different drug or combination of drugs.
The purpose of the study is to see if DNA abnormalities in your cancer or “biomarkers” can help predict how certain cancers may respond to certain treatments.
The first part of this trial uses biomarker testing to identify which substudy, and therefore which treatment, patients will be assigned to.
The purpose of this study is to compare the use of magnetic resonance imaging (MRI) surveillance combined with prophylactic cranial irradiation (PCI) to MRI surveillance alone in treating your lung cancer that can sometimes spread to the brain.
MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain.
The usual treatment approach for lung cancer that has spread after treatment is to switch to a different chemotherapy. The purpose of this study is to compare the usual treatment approach to a technique in radiotherapy called stereotactic body radiotherapy (SBRT) while continuing the current treatment of immunotherapy with or without chemotherapy.
The purpose of the study is to identify which non-small cell lung cancer patients would benefit from the addition of chemotherapy to their standard immunotherapy treatment. Researchers want to understand if patients who have the chemotherapy added are getting maximum potential benefit with less risk of side effects.
A blood test will be given to identify who would benefit from added chemotherapy by using circulating tumour DNA (ctDNA), which is DNA shed by the patient’s cancer.
The purpose of this study is to compare the effects of the usual approach alone to using the study drug plus the usual approach on you and your skin cancer. The usual treatment for patients with advanced skin cancer is the removal of the cancerous tissue (surgery) with or without radiation.
The purpose of this study is to compare the effects on you and your mucosal melanoma of a new drug with the usual treatment compared to a placebo with the usual treatment.
The purpose of this study is to investigate the effects of adding a new treatment to the standard treatment (immune checkpoint blockade, or ICB) for advanced melanoma compared to the standard treatment given alone.
The purpose of this study is to examine the DNA and RNA found in your blood cells and tumour. Researchers want to understand how the changes in the genome of your tumour before, during and post-treatment affect how your body responds to treatment.
The purpose of this study is to compare the effects on you and your sarcoma of a new immunotherapy drug with chemotherapy to chemotherapy alone, the current standard treatment.
The purpose of this study is to compare the effects of receiving chemotherapy before surgery on you and your sarcoma compared to surgery alone.
This study is being done to answer the following question: For bone cancer, is Stereotactic Body Radiation Therapy (SBRT) better for pain relief than the standard conventional radiation therapy (CRT)?
SRBT is high dose radiation therapy that targets painful areas of cancer, while keeping the radiation away from the healthy tissue around the cancer. CRT is radiation therapy that is directed at the painful area but can negatively affect unaffected areas.
The purpose of this study is to test if a mindfulness program (Mindfulness Based Cancer Survivorship (MBCS) Journey) delivered through a mobile smartphone application (Am Mindfulness) can reduce ongoing psychosocial symptoms such as stress, anxiety, depression, fatigue, and fear of cancer recurrence or progression that are often experienced by survivors.
